Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC)

Authors :: Li Yuan Bai
Hyun Cheol Chung
Shigenori Kadowaki
Shuichi Hironaka
Kaijiro Maeda
Yasuo Hamamoto
Keisho Chin
Yuko Kitagawa
Toshihiro Kudo
Kohei Shitara
Akichika Ozeki
Yoon-Koo Kang
Chia Jui Yen
Do-Youn Oh
Kazuhiro Yoshida
Takaki Yoshikawa
Yasushi Omuro
Kei Muro
Reigetsu Yoshikawa
Source :: Journal of Clinical Oncology. 36:4036-4036
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 4036Background: RAM (a human IgG1 antibody against vascular endothelial growth factor receptor-2) plus paclitaxel has been found to improve overall survival compared with paclitaxel alone as second...

Tools